Abstract:Purpose: A prospective Phase I/II dose escalation study was conducted to determine the maximum tolerated dose (MTD) in three-dimensional conformal radiation therapy (3D-CRT) for non-small-cell lung cancer (NSCLC).Methods and Materials: MTD would be reached via a dose escalation study. After 42 Gy/21 fractions, 4.2 weeks by conventional fractionated irradiation through anteroposterior/posteroanterior fields, the 3D-CRT technique was used as boost. The planned total dose escalation depended on lung volume irradiated. According to the percentage of lung volume receiving >20 Gy, the patients were divided into three subgroups (i.e., <25%, 25%-37%, and >37%). The scheduled dose escalation began with 69 Gy and continued to 78 Gy. The boost doses were delivered at 3 Gy per fraction, once per day, five fractions per week. Each dose level includes 5 patients. Besides radiotherapy, all patients received neoadjuvant and adjuvant chemotherapy with MVP regimen (Mitomycin, Vindesine, cis-platium). The criterion for stopping further dose escalation was greater than or equal to20% of patients with greater than or equal toRTOG Grade 3 radiation pneumonitis.Results: Between June 1999 and February 2001, 50 patients had been enrolled in this study, including 4 with Stage II disease, 31 with Stage IIIa disease, and 15 with Stage IIIb disease. The dose escalation plan has been completed. All subgroups reached the highest predetermined dose levels (i.e., 78 Gy for the <25% subgroup, 78 Gy for the 25-37% subgroup, and 75 Gy for the >37% subgroup). Although none of the subgroups developed more than 20% of greater than or equal toGrade 3 acute pneumonitis, dose escalation was terminated because long-term follow-up was needed to observe late complications. Median follow-up time (NUT) for the entire group was 18 months (6-37 months). The most common acute complication was esophagitis in 56% of patients with RTOG Grade 1-2, and in 4% with Grade 3. Acute radiation pneumonitis developed in 36% of patients with RTOG Grade 1-2. Only 1 patient had Grade 3 pneumonitis, which was in the 25-37% subgroup at 75 Gy. The hematopoietic toxicity appeared in 58% of patients with Grade 1-2, and 8% with Grade 3. As to late complications, only 30% of patients developed pulmonary fibrosis of RTOG Grade 1-2. The median survival time for the entire group was 18 months. Two-year overall survival, locoregional progression-free rate, and distant metastasis rate were 44%, 40%, and 41%, respectively.Conclusion: Although MFT was 18 months, it had not yet been declared because a longer follow-up was needed to observe the late complications. The 2-year overall survival of 44% was very encouraging and implied that 3D-CRT combined with chemotherapy would improve the outcome for locally advanced NSCLC. (C) 2003 Elsevier Inc.

Late Course Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage Ⅲ Non-Small Cell Lung Cancer

Late-course three-dimensional conformal concurrent chemoradiotherapy for 31 patients with non-small cell lung carcinoma

Clinical Study on the Effect of Hypofractionated Three -Dimensional Conformal Radiation Therapy in the Treatment of Non -Small Cell Lung Cancer

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

The Analyses of 81 Patients with Stage Ⅲ Non-Small Cell Lung Cancer Treated by Late Course Accelerated Hyperfractionation Radiotherapy

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Short-term results for inoperable stage Ⅲ non-small cell lung cancer treated with late-course accelerated hyperfractionation radiotherapy

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.

A Phase II Trial of Accelerated Hypofractionated Three-Dimensional Conformal Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer

Three-Dimensional Conformal Radiation Therapy For Non-Small-Cell Lung Cancer: A Phase I/Ii Dose Escalation Clinical Trial

Three-Dimensional Radiation Therapy to the Primary Tumor with Concurrent Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study from PPRA-RTOG, China

Neoadjuvant Chemotherapy Followed by Late-Course Accelerated Hyperfractionated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer: the Long Term Results of a Phase I/II Clinical Trial

Clinical Observation of Three Dimensional Conformal Radiotherapy Concurrently Combined with Chemotherapy for Stage III Non-Small Cell Lung Cancer

Hyperfractionated Radiation Therapy with Concurrent Low-Dose Weekly Carboplatin/etoposide for Stage III Non-Small-cell Lung Cancer:A Randomized Study

A prospective, multicenter, phase II clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer-PPRA-RTOG003

Concurrent paclitaxel or/and carboplatin with radiotherapy for stageⅢnon-small cell lung cancer

Research of three-dimensional conformal radiotherapy combined with concurrent weekly oxaliplatin for inoperable stage Ⅲ non-small cell lung cancer

Randomized trial of hyperfractionated plus accelerated hyperfractionated radiation therapy with or without concomitant chemotherapy for stage III A / III B non-small-cell lung cancer: A preliminary result

Analysis on the Time of Free Disease and Impact Factors of Stage Ⅲ of Non-small Cell Lung Cancer Treated with Late Course Comformal Radiotherapy

Comparison of Late-course three Dimensional Conformal Radiation Therapy and Conventional Fractionation for Nasopharyngeal Carcinoma

Clinical Study of Three-Dimensional Conformal Radiotherapy Combined with Concurrent and Sequential Gemcitabine Chemotherapy for Stage Ⅲ Non-Small Cell Lung Cancer in Elderly Patients